Public Information

Health Canada approves PLUVICTO™ as first targeted radioligand therapy for progressive PSMA positive metastatic castration-resistant prostate cancer

Health Canada has authorized PLUVICTO™ for the treatment of certain patients with progressive, prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer.

Specifically, PLUVICTO™ has been approved for the treatment of adult patients with PSMA-positive mCRPC who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy.

The press release to announce this news is available HERE:

Health Canada approves PLUVICTO as first targeted radioligand therapy for progressive PSMA positive metastatic castration-resistant prostate cancer | Novartis Canada

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

INESSS DaTscan recommendation

The Quebec’s Institut national d'excellence en santé et en services sociaux (INESSS) became the first Canadian health technology assessment organization to review DaTscan ([123I]ioflupane)and has provided a positive reimbursement recommendation.